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CASE DESCRIPTION
A 32-year-old man with an unremarkable medical history presented to the ambulatory clinic with complaints
of nonlocalized abdominal pain. The results of a physical examination were unremarkable. The results
obtained from liver, pancreatic, and renal testing were within the reference intervals, and the results of both
a fecal occult blood test and an investigation for parasites in the stool were negative. Laboratory investigations
also revealed a plasma carbohydrate antigen 19-9 (CA19-9) concentration of 3103 IU/mL (reference interval,
2– 40 IU/mL). After this finding, abdominal ultrasonography and nuclear magnetic resonance imaging eval-
uations were made.
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Fig. 1. Imaging study showing the splenic cyst (arrow).
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QUESTIONS
1. Is CA19–9 increased only in malignancy?
2. What nonmalignant conditions can give rise to increased plasma CA19–9?
The answers are below.
ANSWERS
CA19–9 can be increased in malignant and nonmalig-
nant disease. Nonmalignant causes include biliary tract
obstruction, cholangitis, inflammatory bowel disease,
acute or chronic pancreatitis, cirrhosis, and cystic fi-
brosis. Imaging (Fig. 1) and histologic findings were
consistent with a giant benign epidermoid splenic cyst
(13.5 cm in diameter). One month after total splenec-
tomy, the CA19–9 concentration was within the refer-
ence interval. Owing to its low diagnostic specificity
(1 ), the measurement of CA19–9 is suggested only for
the follow-up of known gastrointestinal, biliary, or
pancreatic cancers (2, 3 ); however, splenic cyst is a rare
benign cause of CA19–9 increase (4, 5 ) that should not
be overlooked.
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